الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 241 |  |  |
| | | from | 241 | | |
Abstract
Proliferative vitreoretinopathy [PVR] is a disease process at occurs in eyes with rhegmatogenous retinal detachment and ccounts for the majority of failures following retinal detachment Isurgery. Various surgical procedures have been used to repair retinal etachment associated with PVR. Up to 74% of cases can be iuccessful ly treated. Recent investigations have been directed toward the iarmacological inhibition of PVR. Different pharmacological ents have been investigated including; steroids to suppress ular inflammation and cellular proliferation; Cytotoxic fluoropyrimidines and daunorubicin, that act on one or phases of the cycle of cell growth to inhibit cell o1iferation; anticytoskeletal agents, coichicine, taxol and tochalasin B, to inhibit cell migration and contraction; RGDS and parin to inhibit cell attachment to collagen and BetaLnoproptonitrile, cis- hydroxyproline and penicillamine to reduce racellular matrix formation. Pharmacological therapy of PVR may require specialized Lques for drug delivery to decrease drug toxicity to normal r tissues and to enhance drug effectiveness.